Lifordi gets new funding from Sanofi Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 18 November, 2025

The hematology sector heads into ASH under pressure, with data that could reshape R&D strategies and investment decisions across blood disorders. Join our expert analysis of the year’s most consequential readouts. Sign up today.

presented by Where ded­i­ca­tion de­liv­ers ex­cel­lence in bi­o­log­ics

news Roche’s oral SERD delays early breast cancer recurrence in late-stage trial Exclusive: Lifordi gets new funding from Sanofi as it preps to test ADC in rheumatoid arthritis Vanda says its drug can halve vomiting risk in patients using GLP-1s Exclusive: AI Proteins raises $42M Series A, and will launch miniproteins into hub-and-spoke model

Dec 02 1:00pm ET Navigating JPM 2026: Biotech/biopharma trends, policy impacts & a forward look into the year sponsored by Real Chemistry Dec 03 10:30am ET AI & multi-omics for translational research sponsored by Precision for Medicine

Wednesday: Bring your rare disease drug to the Japanese market — join PMDA officials to map the path forward. Find out how — get your spot.

endpoints pharma New US trade deal caps Switzerland, Liechtenstein pharma tariffs at 15% Novo Nordisk lowers self-pay prices for weight loss drugs ahead of Lilly, TrumpRx Drugmakers say HHS' 340B pilot is limited as they fight for their own rebate models Despite getting a CRL, Scholar Rock expects to launch spinal muscular atrophy drug next year Zymeworks and Jazz tout HER2 bispecific success in first Phase 3 readout

in case you missed it 1. Five takeaways after Merck's $9.2B Cidara deal: More M&A, 'diversified' growth, shifting production to the US 2. Exclusive: AI can dream up molecules. Terray develops a way to figure out which ones to make 3. J&J to buy Halda for $3.05B, adding startup's RIPTAC cancer drug 4. News Briefing How the Lilly-Adverum deal came together; Captain T Cell reels in €20M 5. Lilly makes up to $2.6B pact with South Korean biotech 6. Solve Therapeutics rakes in $120M for two mystery ADCs 7. Jeffrey Bluestone hands Sonoma CEO post to Stephen Dilly 8. Artios Pharma raises $115M for DNA damage response programs